Global Expansion Medinol has a growing footprint with U.S. presence and distribution partnerships, notably the May 2023 US distribution agreement for EluNIR through CoSo Health, signaling opportunities to expand direct sales, pricing negotiations, and training programs in North America.

EluNIR Advantage The elastomeric EluNIR drug-eluting stent with thin struts, proprietary coating, and Flexx² catheter technology offers a compelling clinical and delivery performance narrative that can be leveraged to open new hospital accounts and insurances focused on safer, easier deployments.

In-House Quality In-house manufacturing and proprietary processes underline strong quality and safety narratives that can support competitive bidding in hospital procurement, highlight reliability during RFPs, and facilitate discussions around supply continuity and regulatory compliance.

Clinical Validation Two clinical studies showing favorable safety and outcomes provide talking points for clinical champions and KOL engagements, supporting opportunities to run investigator-initiated studies or co-marketing with key cardiology centers.

Growth Readiness With leadership continuity from founders and a mid-sized employee base, Medinol is positioned to scale partnerships and channel programs, including distribution expansions, training services, and added-value support for hospitals adopting EluNIR.